Skip to main content
Nephron is fully inspected, and approved by the FDA!
Close

Nephron Pharmaceuticals Corp. Addresses Nationwide Shortage of Sodium Bicarbonate Injection

May 31, 2017 Nephron's main entrance and lobby

Nephron Pharmaceuticals Corporation (Nephron) will address the recently announced critical drug shortage of 8.4% Sodium Bicarbonate Injection, USP on Friday, June 2, 2017.

This medication is available for pre-order as of Wednesday, May 31, and will ship from the Nephron 503B Outsourcing Facility on June 2, 2017.

Nephron has prepared this sterile injectable drug, to help alleviate this critical nationwide drug shortage.  The Company is only the third supplier in the country to produce 8.4% Sodium Bicarbonate Injection, USP.

The 503B Outsourcing Facility at Nephron is FDA inspected and operates certified clean rooms using current Good Manufacturing Practices (cGMP).  All products are manufactured on fully validated equipment and are verified with advanced in-house analytical and microbiological testing.

The new division has tripled in size since launch in January 2017 and distributes nationwide.      

Nephron produces 1+ billion sterile doses annually from its award winning West Columbia, South Carolina location.

Hospitals and surgery centers can contact the Nephron 503B Outsourcing Facility toll free at 1-844-224-2225 or email customerservice@nephronpharm.com.